Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility

AIDS Research and Human Retroviruses

Volumn 24, Issue 10, 2008, Pages 1291-1300

  Trivedi, Vinod ^a   Von Lindern, Jana ^a   Montes Walters, Miguel ^a   Rojo, Daniel R ^a   Shell, Elisabeth J ^a   Parkin, Neil ^b   O'Brien, William A ^a,c   Ferguson, Monique R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b Monogram Sciences Inc   (United States)

^c Research Think Tank Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC SENSITIVITY; ARTICLE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN;

DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MUTATION, MISSENSE; RECOMBINATION, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VIRUS REPLICATION;

EID: 53849136952     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0244     Document Type: Article

References (61)

1. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
2. Smith D, Moini N, Pesano R, Cachay E, Aiem H, Lie Y, et al.: Clinical utility of HIV standard genotyping among antiretroviral-naive individuals with unknown duration of infection. Clin Infect Dis 2007;44:456-458.
3. Quiros-Roldan E, Moretti F, Airoldi M, Fausti C, Chiodera A, Castelli F, et al.: Long-term benefit of genotypic-guided therapy and prevalence of multinucleoside resistance in an Italian group of antiretroviral multiexperienced patients. J Clin Lab Anal 2001;15:127-130.
4. Rousseau MN, Vergne L, Montes B, Peeters M, Reynes J, Delaporte E, et al.: Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;26:36-43.
5. Winters MA, Baxter JD, Mayers DL, Wentworth DN, Hoover ML, Neaton JD, et al.: Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS. Antiviral Ther 2000;5:57-63.
6. Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, et al.: Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study. AIDS 1999;13:F17-21.
7. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, et al.: Drug resistance mutations in HIV-1. Top HIV Med 2003;11:92-96.
8. Richman DD, Morton SC, Wrin T, Hellmann N, Berry S, Shapiro MF, et al.: The prevalence of antiretroviral drug resistance in the United States. AIDS 2004;18:1393-1401.
9. Mansky LM, Pearl DK, and Gajary LC: Combination of drugs and drug-resistant reverse transcriptase results in a multiplicative increase of human immunodeficiency virus type 1 mutant frequencies. J Virol 2002;76:9253-9259.
10. Mansky LM: Mutagenic outcome of combined antiviral drug treatment during human immunodeficiency virus type 1 replication. Virol 2003;307:116-121.
11. Whitcomb JM, Parkin NT, Chappey C, Hellmann NS, and Petropoulos CJ: Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003;188:992-1000.
12. Schooley RT, Ruane P, Myers RA, Beall G, Lampiris H, Berger D, et al.: Tenofovir DF in antiretroviral-experienced patients: Results from a 48-week, randomized, double-blind study. AIDS 2002;16:1257-1263.
13. Squires K, Pozniak AL, Pierone G Jr, Steinhart CR, Berger D, Bellos, NC, et al.: Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial. Ann Intern Med 2003;139:313-320.
14. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA 2004;292:191-201.
15. Miller MD, Margot N, Lu B, Zhong L, Chen S, Cheng A, et al.: Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004;189:837-846.
16. Molina JM, Marcelin AG, Pavie J, Heripret L, De Boever CM, Troccaz M, et al.: Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: A randomized placebo-controlled trial. J Infect Dis 2005;191:840-847.
17. Marcelin AG, Flandre P, Pavie J, Schmidely N, Wirden M, Lada O, et al.: Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005;49:1739-1744.
18. Tisdale M, Kemp SD, Parry NR, and Larder BA.: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993;90:5653-5656.
19. Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al.: Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995;333:1662-1669.
20. Catucci M, Venturi G, Romano L, Riccio ML, De Milito A, Valensin PE, et al.: Development and significance of the HIV-1 reverse transcriptase M184V mutation during combination therapy with lamivudine, zidovudine, and protease inhibitors. J Acquir Immune Defic Syndr 1999;21:203-208.
21. Ross L, Parkin N, Chappey C, Fisher R, Clair MS, Bates M, et al.: Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance. AIDS 2004;18:1691-1696.
22. Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein D, et al.: Phenotypic hypersusceptibility to nonnucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: Impact on virological response to efavirenz-based therapy. AIDS 2001;15:1125-1132.
23. Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, and Katzenstein DA: Genetic correlates of efavirenz hypersusceptibility. AIDS 2004;18:1781-1785.
24. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, et al.: The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: A prospective cohort analysis. AIDS 2002;16:F33-40.
25. Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, et al.: Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: Clinical, phenotypic and genotypic correlates. AIDS 2002;16:F41-47.
26. Shi C and Mellors JW: A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob Agents Chemother 1997;41:2781-2785.
27. Adachi A, Gendelman E, Koenig S, Folks T, Willey R, Rabson A, et al.: Production of acquired immunodeficiency syndrome-associated retrovirus in human and non-human cells transfected with an infectious molecular clone. J Virol 1986;59:284-291.
28. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al.: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44:920-928.
29. Parkin N, Chappey C, Maroldo L, Bates M, Hellmann NS, and Petropoulos CJ: Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J Acquir Immune Defic Syndr 2002;31:128-136.
30. Campbell TB, Schneider K, Wrin T, Petropoulos CJ, and Connick E: Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J Virol 2003;77:12105-12112.
31. Dykes C, Fox K, Lloyd A, Chiulli M, Morse E, and Demeter LM: Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology 2001;285:193-203.
32. Wainberg MA: The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther 2004;2:147-151.
33. Huang W, Gamarnik A, Limoli K, Petropoulos CJ, and Whitcomb JM: Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol 2003;77:1512-1523.
34. Boyer PL, Gao HQ, and Hughes SH: A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob Agents Chemother 1998;42:447-452.
35. Uhlmann EJ, Tebas P, Storch GA, Powderly WG, Lie YS, Whitcomb JM, et al.: Effects of the G190A substitution of HIV reverse transcriptase on phenotypic susceptibility of patient isolates to delavirdine. J Clin Virol 2004;31:198-203.
36. Harrigan PR, Mo T, Wynhoven B, Hirsch J, Brumme Z, McKenna P, et al.: Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2005;19:549-554.
37. Meyer PR, Pfeifer I, Matsuura S, and Scott WA: Effects of M41L and T215Y mutations in HIV-1 reverse transcriptase on removal of chain-terminators from blocked primer/templates. Antiviral Ther 2000;(Suppl. 3):14.
38. Naeger LK, Margot NA, and Miller MD: ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2002;46:2179-2184.
39. Campbell TB, Johnson SC, Zolopa AR, Young RK, Bushman L, et al.: Antiviral activity of lamivudine in salvage therapy for multi-drug resistant HIV-1 infection. Clin Infect Dis 2005;41:236-242.
40. Meyer PR, Matsuura SE, Mian AM, So AG, and Scott WA: A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Mol Cell 1999;4:35-43.
41. Boyer PL, Sarafianos SG, Arnold E, and Hughes SH: Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 2001;75:4832-4842.
42. Diallo K, Gotte M, and Wainberg MA: Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2003;47:3377-3383.
43. Frankel FA, Marchand B, Turner D, Gotte M, and Wainberg, MA: Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2005;49:2657-2664.
44. Frankel FA, Invernizzi CF, Oliveira M, and Wainberg MA: Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS 2007;21:665-675.
45. Margot NA, Waters JM, and Miller MD: In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother 2006;50:4087-4095.
46. St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, et al.: Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991;253:1557-1559.
47. Sharma PL and Crumpacker CS: Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol 1997;71:8846-8851.
48. Sharma PL and Crumpacker CS: Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: A comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J Virol 1999;73:8448-8456.
49. Miranda LR, Gotte M, Liang F, and Kuritzkes DR: The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob Agents Chemother 2005;49:2648-2656.
50. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, et al.: Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997;276:960-964.
51. Kleim JP, Rosner M, Winkler I, Paessens A, Kirsch R, Hsiou Y, et al.: Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74→Val or Ile and Val-75→Leu or Ile) HIV-1 mutants. Proc Natl Acad Sci USA 1996;93:34-38.
52. Balzarini J, Karlsson A, Meichsner C, Paessens A, Riess G, De Clercq E, et al.: Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. J Virol 1994:68:7986-7992.
53. Fan N, Rank KB, Slade DE, Poppe SM, Evans DB, Kopta LA, et al.: A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Biochemistry 1996;35:9737-9745.
54. Kleim JP, Bender R, Kirsch R, Meichsner C, Paessens A, and Riess G: Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology 1994;200:696-701.
55. Bazmi HZ, Hammond JL, Cavalcanti SC, Chu CK, Schinazi RF, and Mellors JW: In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane- guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 2000;44:1783-1788.
56. Henry M, Tourres C, Colson P, Ravaux I, Poizot-Martin I, and Tamalet C: Coexistence of the K65R/L74V and/or K65R/T215Y mutations on the same HIV-1 genome. J Clin Virol 2006;37:227-230.
57. Parikh UM, Zelina S, Sluis-Cremer N, and Mellors JW: Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase. AIDS 2007;21:1405-1414.
58. Parikh UM, Bacheler L, Koontz D, and Mellors JW: The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006;80:4971-4977.
59. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, et al.: Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004;189:51-60.
60. Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, et al.: Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness. Ann Intern Med 2001;134:440-450.
61. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al.: Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: A randomized trial. AIDS 2002;16:727-736.